Literature DB >> 9252983

Adenosine A2A agonists: a potential new type of atypical antipsychotic.

R Rimondini1, S Ferré, S O Ogren, K Fuxe.   

Abstract

The systemic intraperitoneal (i.p.) administration of the adenosine A2A agonist CGS 21680 was found to dose-dependently antagonize spontaneous and amphetamine-induced (1 mg/kg i.p.) motor activity with similar ED50 values (about 0.2 mg/kg). The ratios between the ED50 values for induction of catalepsy and for antagonizing amphetamine-induced motor activity for CGS 21680, haloperidol, and clozapine were 12, 2, and > 30, respectively. Furthermore, CGS 21680 was comparably much stronger than haloperidol or clozapine at antagonizing the motor activity induced by phencyclidine (2 mg/kg subcutaneously) than motor activity induced by amphetamine (1 mg/kg i.p.). In conclusion, the present results show a clear "atypical" antipsychotic profile of the adenosine A2A agonist CGS 21680 in animal models.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252983     DOI: 10.1016/S0893-133X(97)00033-X

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  47 in total

1.  Long-term proline exposure alters nucleotide catabolism and ectonucleotidase gene expression in zebrafish brain.

Authors:  Luiz Eduardo Baggio Savio; Fernanda Cenci Vuaden; Denis B Rosemberg; Maurício R Bogo; Carla Denise Bonan; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2012-06-07       Impact factor: 3.584

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 3.  Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.

Authors:  Sergi Ferré
Journal:  Psychopharmacology (Berl)       Date:  2016-01-20       Impact factor: 4.530

4.  Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats.

Authors:  B A Baldo; G F Koob; A Markou
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

Review 5.  Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.

Authors:  Kjell Fuxe; Sergi Ferré; Meritxell Canals; Maria Torvinen; Anton Terasmaa; Daniel Marcellino; Steven R Goldberg; William Staines; Kirsten X Jacobsen; Carmen Lluis; Amina S Woods; Luigi F Agnati; Rafael Franco
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 6.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 7.  Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain.

Authors:  S Ferré; I Diamond; S R Goldberg; L Yao; S M O Hourani; Z L Huang; Y Urade; I Kitchen
Journal:  Prog Neurobiol       Date:  2007-05-01       Impact factor: 11.685

Review 8.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

Review 9.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

10.  Adenosinergic regulation of striatal clock gene expression and ethanol intake during constant light.

Authors:  Christina L Ruby; Chelsea A Vadnie; David J Hinton; Osama A Abulseoud; Denise L Walker; Katheryn M O'Connor; Maria F Noterman; Doo-Sup Choi
Journal:  Neuropsychopharmacology       Date:  2014-04-23       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.